The study population consists of adults aged ≥65 years with laboratory-confirmed invasive pneumococcal disease (IPD). Participants are excluded if serotype or vaccine history data are missing. Participants who received PCV13, PCV15 or PPV23 in the past 5 years are not eligible for PCV20 effectiveness assessment. Serotypes monitored are those included in the PCV20 vaccine (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F). All sites are expected to provide a minimum of 1 year and up to 4 years of data.
The network currently includes sites in Spain (Catalan Hospital Network, Galicia, Madrid, Valencia), the Czech Republic, and Israel, where PCV20 was approved in 2022 or 2023. Assuming PCV20 uptake of 10–20%, with 264-757 participants per site and an estimated 64% of IPD caused by PCV20 serotypes, vaccine effectiveness of around 65% is expected to be detected with 30-40% precision. However, as the total number of participants is expected to exceed 3,000, the precision of effectiveness estimates will likely be higher.
The authors concluded: “IPD-VEN is expanding its scope to include paediatric pneumococcal vaccine evaluation, with ten candidate sites, including the United States. The network remains open to new paediatric study sites beyond the current geographic scope.”
- Kagia C, et al. IPD-VEN, a new multicountry network to evaluate pneumococcal conjugate vaccines against invasive pneumococcal disease. 6th ESCMID Vaccines, 10–13 September 2025, Lisbon, Portugal.
Medical writing support was provided by Mihai Surducan, PhD.
Copyright ©2025 Medicom Medical Publishers
Posted on
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com